Trial of JZP 110 shows abuse potential differs from traditional stimulants directed to narcolepsy.- Jazz Pharma

Jazz Pharmaceuticals announced results from a Human Abuse Liability (HAL) study of JZP 110, an investigational wake-promoting agent in Phase III development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). "The new data from the HAL study demonstrated that each of the doses of JZP-110 that were studied, including the high therapeutic dose of 300 mg and the supratherapeutic doses of 600 mg and 1200 mg, had consistently lower ratings on the primary endpoint of Peak Liking at the Moment and on the secondary endpoints of Overall Drug Liking and willingness to Take the Drug Again compared to the Schedule IV stimulant phentermine at 90 mg," said Jack Henningfield, Ph.D., vice president at Pinney Associates and professor at Johns Hopkins University School of Medicine.

"JZP-110 has a mechanism of action that is distinct from traditional stimulants and these data showed that the abuse potential of JZP-110 differed from that of a traditional stimulant as well." The data will be presented at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting.